Kumar, B N Prashanth <br/><br/>
Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling.  [electronic resource] 

 -  BMC cancer  Jun 2013 
 - 273 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-13-273  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Autocrine Communication--drug effects<br/>Blotting, Western<br/>Breast Neoplasms--metabolism<br/>Celecoxib<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Female<br/>Humans<br/>Mice<br/>Neovascularization, Pathologic--chemically induced<br/>Pyrazoles--administration & dosage<br/>Reactive Oxygen Species--metabolism<br/>Receptors, Vascular Endothelial Growth Factor--metabolism<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Signal Transduction--drug effects<br/>Sulfonamides--administration & dosage<br/>Tamoxifen--administration & dosage<br/>Transfection<br/>Vascular Endothelial Growth Factor A--metabolism<br/>Xenograft Model Antitumor Assays